Compositions and methods for treating disorders associated with loss-of-function mutations in SCN2A

NZ835230APending Publication Date: 2026-07-31PRAXIS PRECISION MEDICINES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
NZ835230
Authority / Receiving Office
NZ · NZ
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-07-22
Filing Date
2021-07-22
Publication Date
2026-07-31

Smart Images

  • Figure 00000100_0000
    Figure 00000100_0000
  • Figure 00000101_0000
    Figure 00000101_0000
  • Figure 00000101_0001
    Figure 00000101_0001
Patent Text Reader

Abstract

Provided herein are methods for increasing levels of SCN2A protein in a cell, comprising contacting the cell with an antisense oligonucleotide that enhances splicing at a splice site of a retained intron in an intron-retaining SCN2A mRNA or pre-mRNA, wherein the retained intron is selected from among intron 1, 2, 3, 4, 5, 11, 13, 17 and 24 and wherein the antisense oligonucleotide comprises a sequence of nucleobases that is complementary to a target region in the SCN2A mRNA or pre-mRNA. Also provided are antisense oligonucleotides for use in such methods. Also provided are methods for treating disorders associated with a heterozygous loss-of-function mutation in SCN2A, comprising administering to the subject such antisense oligonucleotides.
Need to check novelty before this filing date? Find Prior Art